



# Pfizer Hosts Virtual-Only Annual Meeting of Shareholders

Thursday, April 23, 2020 - 01:54pm

.q4default .bwalignc { text-align: center; list-style-position: inside; }

## Declares 38-Cent Second-Quarter 2020 Dividend

NEW YORK--(BUSINESS WIRE)-- The board of directors of Pfizer Inc. (NYSE:PFE) today declared a 38-cent second-quarter 2020 dividend on the company's common stock, payable June 5, 2020 to shareholders of record at the close of business on May 8, 2020. The second-quarter 2020 cash dividend will be the 326th consecutive quarterly dividend paid by Pfizer.

"2019 was a successful, purpose-driven and transformational year for Pfizer. We reached more than half a billion patients\* with our medicines and vaccines, received 10 regulatory approvals for either new drugs or new indications, and progressed many of our key R&D pipeline candidates in clinical studies. We also took a series of actions designed to strengthen each of our businesses and transform Pfizer into a singularly focused, science-driven company," stated Albert Bourla, Pfizer Chairman and Chief Executive Officer.

He continued, "During this extraordinarily challenging time, everyone at Pfizer has truly lived their commitment to our purpose: Breakthroughs that change patients' lives, which has taken on an even greater importance given the global impact of COVID-19."

Preliminary results from the Annual Meeting of Shareholders held today in a virtual only-format indicate that the company's 14 director nominees were re-elected to one-year terms and that shareholders ratified the selection of KPMG LLP as Pfizer's independent registered public accounting firm for the 2020 fiscal year. In addition, shareholders supported the board-sponsored proposal to approve, on an advisory basis, the compensation of the company's named executive officers.

In other voting, the shareholder proposals were not approved.

The final results are subject to verification by the independent inspectors of election. The final results will be reported on a Current Report on Form 8-K to be filed by Pfizer with the U.S. Securities and Exchange Commission in the next few days.

Pfizer Inc.: Breakthroughs That Change Patients' Lives®

At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety and value in the discovery, development and manufacture of health care products, including innovative medicines and vaccines. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as one of the world's premier innovative biopharmaceutical companies, we collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For more than 150 years, we have worked to make a difference for all who rely on us. We routinely post information that may be important to investors on our website at [www.Pfizer.com](http://www.Pfizer.com). In addition, to learn more, please visit us on [www.Pfizer.com](http://www.Pfizer.com) and follow us on Twitter at @Pfizer and @Pfizer News, LinkedIn, YouTube and like us on Facebook at [Facebook.com/Pfizer](https://www.facebook.com/Pfizer).

DISCLOSURE NOTICE: The information contained in this release is as of April 23, 2020. The Company assumes no obligation to update forward-looking statements contained in this release as a result of new information or future events or developments.

This release contains forward-looking information about the Company's growth strategy and actions to enhance shareholder value, including their potential benefits, that involves substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Risks and uncertainties include, among other things, the uncertainties inherent in research and development; the uncertainties inherent in business and financial planning, including, without limitation, risks related to Pfizer's business and prospects, adverse developments in Pfizer's markets, or adverse developments in the U.S. or global capital markets, credit markets, regulatory environment or economies generally; the impact of COVID-19 on our business, operations and financial results; and competitive developments.

A further description of risks and uncertainties can be found in Pfizer's Annual Report on Form 10-K for the fiscal year ended December 31, 2019 and in its subsequent reports on Form 10-Q, including in the sections thereof captioned "Risk Factors" and "Forward-

Looking Information and Factors That May Affect Future Results,” as well as in its subsequent reports on Form 8-K, all of which are filed with the U.S. Securities and Exchange Commission and available at [www.sec.gov](http://www.sec.gov) and [www.pfizer.com](http://www.pfizer.com).

\* Patient counts are estimates derived from multiple data sources.

View source version on [businesswire.com](http://businesswire.com):

<https://www.businesswire.com/news/home/20200423005800/en/>

Media Relations: Amy Rose +1 (212) 733-7410 [Amy.Rose@Pfizer.com](mailto:Amy.Rose@Pfizer.com)

Investor Relations: Ryan Crowe +1 (212) 733-8160 [Ryan.Crowe@Pfizer.com](mailto:Ryan.Crowe@Pfizer.com)

Source: Pfizer Inc.